Literature DB >> 8503012

Proliferation of human smooth muscle cells promoted by lipoprotein(a).

D J Grainger1, H L Kirschenlohr, J C Metcalfe, P L Weissberg, D P Wade, R M Lawn.   

Abstract

Elevated blood concentrations of lipoprotein(a) [Lp(a)] and its constituent, apolipoprotein(a) [apo(a)], constitute a major risk factor for atherosclerosis, but their physiological activities remain obscure. Lp(a) and purified apo(a) stimulated the growth of human smooth muscle cells in culture. This effect resulted from inhibition of plasminogen activation, and consequently the activation by plasmin of latent transforming growth factor-beta, which is an inhibitor of smooth muscle cell growth. Because smooth muscle proliferation is one of the hallmarks of atherosclerotic lesions, these results point to a plausible mechanism for the atherogenic activity of Lp(a).

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8503012     DOI: 10.1126/science.8503012

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  46 in total

Review 1.  Lipoprotein(a) and coronary heart disease risk.

Authors:  S M Marcovina; R A Hegele; M L Koschinsky
Journal:  Curr Cardiol Rep       Date:  1999-07       Impact factor: 2.931

2.  Elevated Lipoprotein(a) Levels Lower ABCA1 Cholesterol Efflux Capacity.

Authors:  Hagai Tavori; Alexandra M Fenton; Deanna L Plubell; Sara Rosario; Elisabeth Yerkes; Rayna Gasik; Joshua Miles; Paige Bergstrom; Jessica Minnier; Sergio Fazio; Nathalie Pamir
Journal:  J Clin Endocrinol Metab       Date:  2019-10-01       Impact factor: 5.958

Review 3.  Lipoprotein(a): searching for a function.

Authors:  P C Harpel; M Poon; X Zhang; M B Taubman
Journal:  Trans Am Clin Climatol Assoc       Date:  1996

4.  Abnormal lipoprotein(a) levels predict coronary artery calcification in Southeast Asians but not in Caucasians: use of noninvasive imaging for evaluation of an emerging risk factor.

Authors:  Abhinav Sharma; Manoefris Kasim; Parag H Joshi; Zhen Qian; Eric Krivitsky; Kamran Akram; Sarah Rinehart; Gustavo Vazquez; Joseph Miller; Mohammad Saifur Rohman; Szilard Voros
Journal:  J Cardiovasc Transl Res       Date:  2011-04-12       Impact factor: 4.132

Review 5.  The latent transforming growth factor beta binding protein (LTBP) family.

Authors:  R Oklü; R Hesketh
Journal:  Biochem J       Date:  2000-12-15       Impact factor: 3.857

6.  Plasminogen deficiency accelerates vessel wall disease in mice predisposed to atherosclerosis.

Authors:  Q Xiao; M J Danton; D P Witte; M C Kowala; M T Valentine; T H Bugge; J L Degen
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-16       Impact factor: 11.205

7.  Reduction of cardiovascular risk in subjects with high lipoprotein (a) levels.

Authors:  Giulia Malaguarnera; Saverio Latteri; Vito Emanuele Catania; Michele Malaguarnera
Journal:  J Thorac Dis       Date:  2017-08       Impact factor: 2.895

8.  High Lipoprotein(a) Levels are Associated With Long-Term Adverse Outcomes in Acute Myocardial Infarction Patients in High Killip Classes.

Authors:  Jae Yeong Cho; Myung Ho Jeong; Youngkeun Ahn; Young Joon Hong; Hyung Wook Park; Nam Sik Yoon; Hyun Ju Yoon; Kye Hun Kim; Ju Han Kim; Jeong Gwan Cho; Jong Chun Park; Jung Chaee Kang
Journal:  Korean Circ J       Date:  2010-10-31       Impact factor: 3.243

9.  Behavior of Lp(a) and apoproteins (A1, B, C2, C3, E) during and after therapy with simvastatin.

Authors:  T Sampietro; F Galetta; A Bionda
Journal:  Cardiovasc Drugs Ther       Date:  1995-12       Impact factor: 3.727

Review 10.  TGF-β signaling in the kidney: profibrotic and protective effects.

Authors:  Angara Sureshbabu; Saif A Muhsin; Mary E Choi
Journal:  Am J Physiol Renal Physiol       Date:  2016-01-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.